| 吉非替尼联用中药复方治疗非小细胞肺癌的研究 |
| |
| 引用本文： | 李楠,李剑男.吉非替尼联用中药复方治疗非小细胞肺癌的研究[J].长春中医药大学学报,2018(2):378-380. |
| |
| 作者姓名： | 李楠 李剑男 |
| |
| 作者单位： | 中国人民解放军第455医院,上海,200052
长春中医药大学药学院,长春,130117 |
| |
| 摘 要： | 以吉非替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)在晚期非小细胞肺癌(NSCLC)治疗方面取得了较好的疗效。但是其治疗后出现不良反应及耐药性,严重阻碍了后续治疗。而吉非替尼联合中药复方有显著的减毒增效作用,成为目前研究热点。
|
| 关 键 词： | 吉非替尼 中药复方 非小细胞肺癌 表皮生长因子受体酪氨酸激酶抑制剂 Gefi tinib Chinese medicine compound non-small cell lung cancer EGFR-TKI |
Research of Gefitinib in the treatment of non-small cell lung cancer with traditional Chinese medicine |
| |
| LI Nan,LI Jiannan.Research of Gefitinib in the treatment of non-small cell lung cancer with traditional Chinese medicine[J].Journal of Changchun College of Traditional Chinese Medicine,2018(2):378-380. |
| |
| Authors: | LI Nan LI Jiannan |
| |
| Abstract: | Gefitinib, a epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has achieved good results in the treatment of advanced non-small cell lung cancer (NSCLC). However, the adverse reactions and drug resistance after treatment have seriously hindered. The combination of Gefi tinib and traditional Chinese medicine has significant effect on reducing toxicity and increasing efficiency. It has become a hot research topic at present. |
| |
| Keywords: | |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
